{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:25:59Z","timestamp":1791951959005,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Stability indicating RP-HPLC method was developed and validated for the estimation of finerenone (FIN) in pure and in new tablet dosage form. The proposed approach was applied and validated for determination of (FIN) related substances. Stability studies of (FIN) was carried out using five stress conditions; acid, alkali, oxidation, photodegradation and heat degradation. The chromatographic analysis of (FIN) was based on using mobile phase consist of filtered and degassed mixture of 450mL water, 550mL acetonitrile and 10mL triethylamine with pH adjusted to 7. Phenomenex (C18, 4.6\u2009\u00d7\u2009250\u00a0mm, 5\u00a0\u03bcm) column was used with 0.8 mL\/min flow rate and 40\u00a0\u00b0C column temperature. The UV detection was set at 252\u00a0nm with injection volume (10\u00b5L). The (FIN) retention time was 4.437\u2009\u00b1\u20090.05\u00a0min. The proposed technique was validated according to ICH guidelines with good linearity in ranges (8\u201330\u00a0\u00b5g\/mL) for assay of (FIN) and (0.2\u20131.4\u00a0\u00b5g\/mL) for determination of (FIN) unspecified impurities. The found mean percentage recoveries were 99.74% for (FIN) assay and 99.11% for (FIN) related substance determination which indicate good trueness. The developed approach was successfully applied for the determination of (FIN) in Nexifinerenone<jats:sup>\u00ae<\/jats:sup> film coated tablet dosage form. Good agreement was established when assay results using the validated RP-HPLC method were compared statistically to those obtained using the reported method. For the greenness assessment Complex GAPI, Complex MoGAPI and AGREE methods were applied.<\/jats:p>","DOI":"10.1038\/s41598-025-07166-4","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:19:42Z","timestamp":1750429182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stability indicating RP-HPLC method for estimation of finerenone and its related substances in new dosage form"],"prefix":"10.1038","volume":"15","author":[{"given":"Aya A.","family":"Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed G.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Elshenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"7166_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.ki.5002343","volume":"72","author":"A Levey","year":"2007","unstructured":"Levey, A. et al. Chronic kidney disease as a global public health problem: approaches and initiatives\u2013a position statement from kidney disease improving global outcomes. Kidney Int. 72, 247\u2013259 (2007).","journal-title":"Kidney Int."},{"key":"7166_CR2","doi-asserted-by":"publisher","first-page":"819327","DOI":"10.3389\/fphar.2022.819327","volume":"13","author":"MZ Zhang","year":"2022","unstructured":"Zhang, M. Z., Bao, W., Zheng, Q. Y., Wang, Y. H. & Sun, L. Y. Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. Front. Pharmacol. 13, 819327 (2022).","journal-title":"Front. Pharmacol."},{"key":"7166_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2337\/cd21-0050","volume":"39","author":"LA Marcath","year":"2021","unstructured":"Marcath, L. A. & Finerenone Clin. Diabetes 39, 331\u2013332 (2021).","journal-title":"Clin. Diabetes"},{"key":"7166_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei, H. et al. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine 97, 1\u20137 (2018).","journal-title":"Medicine"},{"key":"7166_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","volume":"81","author":"JE Frampton","year":"2021","unstructured":"Frampton, J. E. Finerenone: first approval. Drugs 81, 1787\u20131794 (2021).","journal-title":"Drugs"},{"key":"7166_CR6","first-page":"211","volume":"16","author":"F Husnain","year":"2023","unstructured":"Husnain, F., Mahboob, P. & Khaleel, M. Estimation and validation of finerenone in dosage form and in bulk drug by spectrophotometric method. Indian Journals. 16, 211\u2013215 (2023).","journal-title":"Indian Journals"},{"key":"7166_CR7","doi-asserted-by":"publisher","first-page":"122643","DOI":"10.1016\/j.jchromb.2021.122643","volume":"1172","author":"G Rohde","year":"2021","unstructured":"Rohde, G., Loewen, S. & Heinig, R. Determination of finerenone\u2013a novel, selective, nonsteroidal mineralocorticoid receptor antagonist\u2013in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a Pharmacokinetic study in venous and capillary human plasma. J. Chromatogr. B. 1172, 122643 (2021).","journal-title":"J. Chromatogr. B"},{"key":"7166_CR8","doi-asserted-by":"crossref","unstructured":"Rishipathak, K. S. a. D. Finerenone API Estimation using RP-HPLC technique and LC-MS characterization of its degradation products. Oriental J. Chemistry 41, 528\u2013540 (2025).","DOI":"10.13005\/ojc\/410222"},{"key":"7166_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.30574\/gscbps.2024.27.1.0128","volume":"27","author":"MM VARADE","year":"2024","unstructured":"VARADE, M. M., Patil, P. R. & Jadhav, R. G. Rp-HPLC method development and validation of finerenone in bulk drug and its formulations. GSC Biol. Pharm. Sci. 27, 214\u2013222 (2024).","journal-title":"GSC Biol. Pharm. Sci."},{"key":"7166_CR10","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.51470\/BCA.2024.24.2.2331","volume":"24","author":"YV Reddy","year":"2024","unstructured":"Reddy, Y. V., Nayak, A., Sangeetha, G., Deepa, M. & Kumta, R. Analytical quality by design approaches to RP-HPLC method development validation and stability indicating assay for the determination of finerenone in bulk drug. Biochem. Cell. Archives. 24, 2331 (2024).","journal-title":"Biochem. Cell. Archives"},{"key":"7166_CR11","first-page":"1","volume":"6","author":"S Naazneen","year":"2024","unstructured":"Naazneen, S., An Isocratic, R. P. H. P. L. C. & Method Development and validation for the quantitative Estimation of finerenone in solid dosage forms. Int. J. Multidisciplinary Res. 6, 1\u20139 (2024).","journal-title":"Int. J. Multidisciplinary Res."},{"key":"7166_CR12","unstructured":"Mukthinuthalapati, A. M. & a., A. & Mathrusri. Forced degradation studies for Estimation of finerenone by RP-HPLC method. World J. Pharm. Life Sciences 5, 91\u201398 (2021)."},{"key":"7166_CR13","doi-asserted-by":"crossref","unstructured":"Imran, S. J. et al. Validated stability indicating reversed-phase high-performance liquid chromatography (RP-HPLC) for the Estimation of finerenone in pharmaceutical tablet dosage form. Europe PMC 46 (2023).","DOI":"10.21203\/rs.3.rs-2984018\/v1"},{"key":"7166_CR14","first-page":"751","volume":"11","author":"VB Metkari","year":"2024","unstructured":"Metkari, V. B. Mrs Vanita gade. method development and validation of finerenone by RP-HPLC method. Int. J. Innovative Res. Technol. 11, 751\u2013761 (2024).","journal-title":"Int. J. Innovative Res. Technol."},{"key":"7166_CR15","doi-asserted-by":"publisher","first-page":"123836","DOI":"10.1016\/j.saa.2024.123836","volume":"309","author":"ST Alsharif","year":"2024","unstructured":"Alsharif, S. T. et al. A fluorescence chemo sensor approach for determination of finerenone in pharmaceutical formulation and human plasma: method development and validation. Spectrochimica Acta Part. A: Mol. Biomol. Spectrosc. 309, 123836 (2024).","journal-title":"Spectrochimica Acta Part. A: Mol. Biomol. Spectrosc."},{"key":"7166_CR16","doi-asserted-by":"publisher","first-page":"111903","DOI":"10.1016\/j.microc.2024.111903","volume":"207","author":"M Locatelli","year":"2024","unstructured":"Locatelli, M. et al. Recent trends in sampling and sorbent-based sample Preparation procedures for bioanalytical applications. Microchem. J. 207, 111903 (2024).","journal-title":"Microchem. J."},{"key":"7166_CR17","doi-asserted-by":"crossref","unstructured":"Teasdale, A., Elder, D., Harvey, J. & Spanhaak, S. Impurities in new drug substances and new drug products: ICH Q3A\/B: key guidelines in the general impurity management process. ICH Qual. Guidelines: Implement. Guide, 6, 167\u2013198 (2017).","DOI":"10.1002\/9781118971147.ch6"},{"key":"7166_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.addr.2006.10.010","volume":"59","author":"AK Basak","year":"2007","unstructured":"Basak, A. K. et al. Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Adv. Drug Deliv. Rev. 59, 64\u201372 (2007).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"7166_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.addr.2006.10.007","volume":"59","author":"D Jacobson-Kram","year":"2007","unstructured":"Jacobson-Kram, D. & McGovern, T. Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev. 59, 38\u201342 (2007).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"7166_CR20","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1039\/D1GC02318G","volume":"23","author":"J P\u0142otka-Wasylka","year":"2021","unstructured":"P\u0142otka-Wasylka, J. & Wojnowski, W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 23, 8657\u20138665 (2021).","journal-title":"Green Chem."},{"key":"7166_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/analytica5030030","volume":"5","author":"FR Mansour","year":"2024","unstructured":"Mansour, F. R., P\u0142otka-Wasylka, J. & Locatelli, M. Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications. Analytica 5, 451\u2013457 (2024).","journal-title":"Analytica"},{"key":"7166_CR22","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical greenness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."},{"key":"7166_CR23","doi-asserted-by":"publisher","first-page":"100068","DOI":"10.1016\/j.sampre.2023.100068","volume":"6","author":"M Locatelli","year":"2023","unstructured":"Locatelli, M. et al. Green profile tools: current status and future perspectives. Adv. Sample Preparation. 6, 100068 (2023).","journal-title":"Adv. Sample Preparation"},{"key":"7166_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jpba.2005.02.037","volume":"38","author":"S k Branch","year":"2005","unstructured":"k. Branch, S. Guidelines from the international conference on harmonisation (ICH). J. Pharm. Biomedical Anal. 38, 798\u2013805 (2005).","journal-title":"J. Pharm. Biomedical Anal."},{"key":"7166_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11094-020-02303-x","volume":"54","author":"N Epshtein","year":"2020","unstructured":"Epshtein, N., Sevast\u2019yanova, V. & Koroleva, A. Validation of Related-Substances determination methods for detecting unidentified substances (A Review). Pharm. Chem. J. 54, 959\u2013967 (2020).","journal-title":"Pharm. Chem. J."},{"key":"7166_CR26","doi-asserted-by":"crossref","unstructured":"Finotti Cordeiro, C., Franco, L., Teixeira Carvalho, L. & Bonfilio, R. D. Impurities in active pharmaceutical ingredients and drug products: A critical review. Critical Reviews Anal. Chemistry, 2024, 1\u201321 (2024).","DOI":"10.1080\/10408347.2024.2384046"},{"key":"7166_CR27","doi-asserted-by":"publisher","first-page":"e00206","DOI":"10.1016\/j.teac.2023.e00206","volume":"39","author":"Y Syrgabek","year":"2023","unstructured":"Syrgabek, Y., Alimzhanova, M., Garc\u00eda-Encina, P. A., Jim\u00e9nez, J. J. & L\u00f3pez-Serna, R. Greenness evaluation of sample Preparation methods by GAPI for the determination of pesticides in grape: A review. Trends Environ. Anal. Chem. 39, e00206 (2023).","journal-title":"Trends Environ. Anal. Chem."},{"key":"7166_CR28","doi-asserted-by":"publisher","first-page":"100178","DOI":"10.1016\/j.greeac.2024.100178","volume":"12","author":"TA Zughaibi","year":"2025","unstructured":"Zughaibi, T. A. & Al-Asmari, A. I. Study of adsorption potential of cellulose paper for abusable prescription drug analysis: A practical and sustainable approach validated by BAGI and ComplexMoGAPI tools. Green. Anal. Chem. 12, 100178 (2025).","journal-title":"Green. Anal. Chem."},{"key":"7166_CR29","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.sampre.2025.100164","volume":"14","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R., Bedair, A. & Locatelli, M. Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods. Adv. Sample Preparation. 14, 100164 (2025).","journal-title":"Adv. Sample Preparation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07166-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:19:45Z","timestamp":1750429185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07166-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7166"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07166-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20229"}}